Companies / BOC Sciences / Rilotumumab
BOC Sciences

Rilotumumab | BOC Sciences

Rilotumumab is a human IgG2 monoclonal antibody that binds to HGF and inhibits c-Met-mediated signal transduction. Rilotumumab has been investigated as the treatment of solid tumors.

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.
  • See More